Cereno Scientific says Phase IIb EPIMODE trial of CS1 in pulmonary arterial hypertension begins screening patients

PUBT · 1d ago
Cereno Scientific says Phase IIb EPIMODE trial of CS1 in pulmonary arterial hypertension begins screening patients
  • Cereno Scientific flagged progress in two pulmonary hypertension programs as it prepared for investor meetings at Nordic Life Science Days.
  • CS1’s global Phase IIb EPIMODE trial in pulmonary arterial hypertension is screening patients; results have not been presented.
  • CS014 topline results from an FDA-aligned Phase I pharmacokinetic bridging study are expected in Q3 2026; results will be presented later.
  • Positive CS014 readout could support a streamlined move into Phase IIb in PH-ILD, with trial initiation planned for Q3 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cereno Scientific AB published the original content used to generate this news brief on September 08, 2026, and is solely responsible for the information contained therein.